Grethe Nørskov Rasmussen
Corporate Officer/Principal bij FLUOGUIDE A/S
Vermogen: 2 M $ op 31-05-2024
Profiel
Grethe Nørskov Rasmussen is currently the Chief Development Officer at FluoGuide A since 2019.
Prior to this, she was the Senior Vice President-Product Development at Ascendis Pharma A from 2008 to 2019.
Before that, she worked as the Vice President-Protein Science at Maxygen, Inc. from 2000 to 2007 and as a Principal at Novo Nordisk A from 1989 to 2000.
Dr. Rasmussen earned her doctorate degree from the Technical University of Denmark in 1989.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
FLUOGUIDE A/S
3.06% | 30-09-2023 | 373 185 ( 3.06% ) | 2 M $ | 31-05-2024 |
Actieve functies van Grethe Nørskov Rasmussen
| Bedrijven | Functie | Begin |
|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 01-01-2019 |
Eerdere bekende functies van Grethe Nørskov Rasmussen
| Bedrijven | Functie | Einde |
|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 01-01-2019 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Opleiding van Grethe Nørskov Rasmussen
| Technical University of Denmark | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| FLUOGUIDE A/S | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
